【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議 CKD >stage3 之老年人長期使用。

高血壓 (ARB) 治療心衰竭 Heart failure, hypertension, myocardial infarction

Valsartan is an orally active, nonpeptide angiotensin II receptor antagonist (ARB), selective for the AT1 receptor. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor subtype in many tissues (eg, vascular smooth muscle, adrenal gland). Its action is independent of the pathways for angiotensin II synthesis. It has no agonist activity of AT1 and its affinity for the AT1 receptor is approximately 20,000 times greater than for the AT2 receptor.

Elimination half-life: 6 hrs
Excretion: primarily as unchanged drug in the urine (13%) and feces (83%)

Concomitant Aliskiren use in diabetic patients; Hypersensitivity to valsartan or other angiotensin receptor antagonists.

D

Infant risk cannot be ruled out

Hypertension, headache, dizziness, serum BUN raised, serum creatinine raised, cough

80 to 160mg PO QD, maintenance dose can be up to 320mg QD